Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s Oncology Group

Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s... We did not detect an effect of body composition or obesity on daunorubicin PK. We found suggestive associations between FMO3 and GSTP1 haplotypes with daunorubicin PK that could potentially affect efficacy and toxicity. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s Oncology Group

Loading next page...
 
/lp/springer-journals/pharmacokinetics-and-pharmacogenomics-of-daunorubicin-in-children-a-JKGOczMEk0

References (44)

Publisher
Springer Journals
Copyright
Copyright © 2014 by Springer-Verlag Berlin Heidelberg
Subject
Medicine & Public Health; Oncology; Pharmacology/Toxicology; Cancer Research
ISSN
0344-5704
eISSN
1432-0843
DOI
10.1007/s00280-014-2535-4
pmid
25119182
Publisher site
See Article on Publisher Site

Abstract

We did not detect an effect of body composition or obesity on daunorubicin PK. We found suggestive associations between FMO3 and GSTP1 haplotypes with daunorubicin PK that could potentially affect efficacy and toxicity.

Journal

Cancer Chemotherapy and PharmacologySpringer Journals

Published: Oct 1, 2014

There are no references for this article.